Protalix Biotherapeutics Inc Updates On PRX-102 - Corporate Call Transcript

Jun 02, 2021 / 05:30AM GMT
Operator

Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Conference Call regarding the clinical development of PRX-102 for the treatment of Fabry disease. As a reminder, this conference call is being recorded.

I will now turn the conference over to our host, Mr. Chuck Padala of LifeSci Advisors, Investor Relations. You may begin your conference.

Charles Padala -

All right. Thank you, Rob. Welcome to the Protalix Conference Call regarding the clinical development of PRX-102 for the treatment of Fabry disease. With me today are Dror Bashan, President and CEO of Protalix; and Eyal Rubin, Chief Financial Officer. Mr. Bashan and Mr. Rubin are joined today by Mr. Ulrich Granzer, PhD, of Granzer Regulatory Consulting & Services. The agency provides Protalix and Chiesi with consulting services related to drug development and regulatory affairs.

Dr. Granzer is a founding member of the German Association of Regulatory Affairs, where he is the current President of the Board and Co-Founder of the European Union Regulatory Affairs Group

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot